New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium aurothiomalate monohydrate 10mg;   - solution for injection - 10 mg - active: sodium aurothiomalate monohydrate 10mg   excipient: nitrogen phenylmercuric nitrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium aurothiomalate monohydrate 20mg;   - solution for injection - 20 mg - active: sodium aurothiomalate monohydrate 20mg   excipient: nitrogen phenylmercuric nitrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium aurothiomalate monohydrate 50mg;   - solution for injection - 50 mg - active: sodium aurothiomalate monohydrate 50mg   excipient: nitrogen phenylmercuric nitrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - codeine phosphate hemihydrate 9.75mg; doxylamine succinate 5mg;  ;  ; paracetamol 450mg;   - tablet - 9.75mg/5mg/450mg - active: codeine phosphate hemihydrate 9.75mg doxylamine succinate 5mg     paracetamol 450mg   - for patients over the age of 12 for the symptomatic relief of acute moderate to severe pain including headache, toothache, backache or pain associated with trauma or surgery. the calmative properties may be especially useful in the treatment of tension headache, migraine and period pain and the antipyretic properties may be useful in controlling fever. mersyndol is a suitable alternative for those individuals who cannot tolerate aspirin.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - aflibercept 25 mg/ml;   - concentrate for infusion - 25 mg/ml - active: aflibercept 25 mg/ml   excipient: citric acid dibasic sodium phosphate heptahydrate hydrochloric acid monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sodium citrate dihydrate sodium hydroxide sucrose water for injection - zaltrap in combination with irinotecan-fluoropyrimidine-based chemotherapy is indicated in adults with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - aflibercept 25 mg/ml;   - concentrate for infusion - 25 mg/ml - active: aflibercept 25 mg/ml   excipient: citric acid dibasic sodium phosphate heptahydrate hydrochloric acid monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sodium citrate dihydrate sodium hydroxide sucrose water for injection - zaltrap in combination with irinotecan-fluoropyrimidine-based chemotherapy is indicated in adults with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 450mg - tablet - 450 mg - active: rifampicin 450mg